Patient Advocacy: Optimizing Advocacy Partnerships to Improve Access and Boost Patient Voice in the United States

• Understanding the advocacy landscape
• Effective practices for working with potentially hostile patient advocacy groups
• Measuring effectiveness
• Advocacy lessons learned from socially sensitive or stigmatized disease areas

• Which of the listed metrics do you think are effective for measuring the success of your patient advocacy activities and relationships?
• Please rate the effectiveness of various approaches designed to help the company, therapeutic areas, and individual brand teams coordinate relationships with patient advocacy groups
• Please rate the effectiveness of the listed methods for prioritizing objectives when a patient advocacy group maintains relationships with multiple brands or therapeutic areas
• Based on your experiences, rate the importance of patient advocacy collaborations at different lifecycle stages
• Which of the listed forms of education, program support, and grants/sponsorships would you consider most important during each of four key lifecycle stages?
• Which approaches work best to deploy advocacy grants/sponsorships for early-stage support with advocacy groups?
• What considerations are most critical when managing collaboration with an advocacy group regarding therapies that may trigger controversy or social stigma?
• What approaches are most effective in educating the market on conditions that may be highly controversial or have a social stigma?
• Were there any patient advocacy, religious or other special interest groups that had a much greater impact than expected on a therapy with which you were involved?
• What strategy or tactics do you find most effective in minimizing opposition from patient advocacy or other special interest groups against a therapy that could be considered controversial?

• Assessing the best tools to manage advocacy relationships: Designating single relationship owner and transparency & authenticity is the key to effectively coordinating relationships with patient advocacy groups, according to more than 60% of the participants. Managing relationships with advocacy groups also benefits from clear roles and responsibilities.

Best Practices, LLC engaged 48 leaders supporting patient advocacy initiatives at 43 biopharmaceutical companies in the United States through a benchmarking survey.

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.